Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.43 |
| ▸ | RBP4 | P02753 | 3/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 5/20 | 0.41 |
| ▸ | XDH | P47989 | 3/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30624264 | 0.85 | GPR119 (0.58) | GPR119 | |
| SCHEMBL30624457 | 0.83 | GPR119 (0.41) | GPR119RBP4IRAK4CYP3A4CYP2D6 | |
| SCHEMBL26601448 | 0.82 | RBP4 (0.42) | RBP4IRAK4JAK3CYP3A4CYP2D6 | |
| SCHEMBL21179334 | 0.81 | GPR6 (0.41) | GPR119ELANE | |
| SCHEMBL21179390 | 0.81 | GPR6 (0.41) | GPR119ELANE | |
| SCHEMBL22588650 | 0.81 | IRAK4 (0.44) | IRAK4 | |
| SCHEMBL22588613 | 0.81 | IRAK4 (0.44) | IRAK4 | |
| SCHEMBL25317956 | 0.79 | CHRNB2 (0.41) | GPR119IRAK4XDHELANE | |
| SCHEMBL22588495 | 0.79 | CHRNB2 (0.41) | GPR119IRAK4XDHELANE | |
| SCHEMBL22588521 | 0.79 | CHRNB2 (0.41) | GPR119IRAK4XDHELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023205595-A2 | EGFR INHIBITORS IN CANCER TREATMENT | CELYN THERAPEUTICS, INC (US) | 2023-10-26 | — | — | WO | disclosed |